--- title: "NHWA released its performance for the first half of the year, with a net profit attributable to the parent company of 700 million yuan, an increase of 11.38%" type: "News" locale: "en" url: "https://longbridge.com/en/news/250554406.md" description: "NHWA released its semi-annual report for 2025, with operating revenue of 3.01 billion yuan, a year-on-year increase of 8.93%; net profit attributable to the parent company was 700 million yuan, a year-on-year increase of 11.38%. The net profit excluding non-recurring gains and losses was 699 million yuan, an increase of 10.33%. The basic earnings per share were 0.69 yuan. The company has over 70 research projects underway, with research funding of 395 million yuan, an increase of 23.97%. In terms of innovative drug research and development, among the 17 projects under research, 1 has completed phase III clinical trials, and 2 have completed phase II clinical trials. In the field of generic drugs, 48 projects are underway, with 1 production approval obtained" datetime: "2025-07-29T09:25:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/250554406.md) - [en](https://longbridge.com/en/news/250554406.md) - [zh-HK](https://longbridge.com/zh-HK/news/250554406.md) --- # NHWA released its performance for the first half of the year, with a net profit attributable to the parent company of 700 million yuan, an increase of 11.38% According to the Zhitong Finance APP, NHWA (002262.SZ) released its semi-annual report for 2025, reporting an operating income of 3.01 billion yuan, a year-on-year increase of 8.93%. The net profit attributable to shareholders of the listed company was 700 million yuan, a year-on-year increase of 11.38%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 699 million yuan, a year-on-year increase of 10.33%. The basic earnings per share were 0.69 yuan. During the reporting period, the company had over 70 research projects underway, investing 395 million yuan in research and development, an increase of 23.97% compared to the same period last year, achieving significant research and development results. In terms of innovative drug research and development, the company currently has 17 innovative drug projects under research, including 1 completed Phase III clinical study project (NH600001 emulsion injection); 2 completed Phase II clinical study projects (NHL35700 tablets, YH1910-Z02 injection); 2 Phase II clinical study projects underway (NH102 tablets, YH1910-Z01 nasal spray); 6 Phase I clinical study projects underway (NH130 tablets, NH104 tablets, Protollin nasal spray, NH160030 tablets, NH140068 tablets, NH280105 capsules); 1 project that has obtained a clinical trial notification (sufentanil citrate injection (new indication)); the remaining projects are in the preclinical research stage. In terms of generic drug product development and consistency evaluation, 48 generic drug projects are underway, including 1 project that has obtained a production approval for a generic drug (hydrobromide of vortioxetine tablets); 5 projects for generic drug production are under review (hydrochloride of tapentadol tablets, extended-release oxycodone tablets (abuse-deterrent), ketorolac tromethamine injection, brexpiprazole tablets, dezocine injection); 2 projects have obtained clinical trial notifications for generic drugs (fentanyl citrate oral mucosal film, hydrochloride of tapentadol oral solution); 7 consistency evaluation projects are underway, including 1 project that has passed consistency evaluation (clozapine orally disintegrating tablets), and 2 projects are under review for consistency evaluation (sulpride tablets, hydrochloride of doripenem injection) ### Related Stocks - [002262.CN](https://longbridge.com/en/quote/002262.CN.md) ## Related News & Research - [14:47 ET6th Annual Midwest Design Awards Entry Period Now Open](https://longbridge.com/en/news/286808240.md) - [IPL 2026: How CSK can still qualify for the playoffs after the loss vs LSG?](https://longbridge.com/en/news/286599501.md) - [06:45 ETHouston Area Urban League and Park Street Homes Break Ground on Legacy Oaks at Bland Street](https://longbridge.com/en/news/286897539.md) - [TrumpRx.gov Expands With More Than 600 Generic Medications](https://longbridge.com/en/news/286905168.md) - [](https://longbridge.com/en/news/286948461.md)